Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Zentalis typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior shows moderate volatility around earnings releases, with the stock averaging a 4.77% absolute move on Day 0 and 5.80% on Day +1. Day 0 trading ranges have averaged 7.25%, while Day +1 ranges expand to 13.73%, indicating that initial reactions often give way to larger secondary moves as investors digest the results.

The directional pattern has been inconsistent. Recent reports show muted Day 0 reactions—the May 2026 report produced only a 3.38% gain, while March 2026 saw a 4.71% pop followed by a sharp 21.35% decline the next day. Earlier reports in 2024 triggered more dramatic moves, including a 9.37% Day 0 drop in August 2024 and a 7.94% decline in November 2024, both followed by volatile Day +1 sessions with ranges exceeding 14%.

The data suggests ZNTL's post-earnings behavior is highly sensitive to clinical updates and forward guidance rather than the EPS print itself. Investors should prepare for potential swings in the 5–10% range initially, with the possibility of extended volatility if the report includes material updates on trial timelines, regulatory pathways, or cash burn projections.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.71% expected move through the August 21 expiration, implying a range of $4.46 to $5.31. This is notably higher than the historical Day 0 average move of 4.77% but below the Day +1 average of 5.80%, suggesting options traders are anticipating above-average volatility relative to immediate post-announcement moves but are not pricing in the extreme secondary swings seen in some prior quarters.

Part 3: What Analysts Are Saying

Analyst sentiment on Zentalis has improved recently, with the consensus shifting more bullish over the past month. The stock currently carries 6 Strong Buy ratings and 6 Hold ratings, with no Sell recommendations among the 12 analysts covering the company. This represents an upgrade from one month ago, when only 4 analysts rated ZNTL a Strong Buy. The average recommendation stands at 4.00 (Buy), up from 3.80 a month prior, reflecting growing confidence in the company's clinical pipeline and execution.

The consensus price target sits at $7.10, implying 45.5% upside from the current price of $4.88. Analyst targets range from a low of $4.00 to a high of $11.00, a wide spread that underscores divergent views on the probability and timeline of clinical success. The high-end target suggests some analysts see potential for the stock to more than double if azenosertib achieves accelerated approval and demonstrates strong efficacy in pivotal trials.

The recent sentiment improvement appears tied to tangible clinical progress—specifically the selection of the azenosertib monotherapy dose and initiation of the ASPENOVA Phase 3 trial. Analysts who upgraded their stance likely view these developments as de-risking the regulatory pathway and increasing the probability of near-term value catalysts. However, the persistence of Hold ratings from half the analyst base indicates caution remains around execution risk, competitive dynamics in the WEE1 inhibitor space, and the company's ability to reach key milestones before requiring additional capital.

Part 4: Technical Picture

Zentalis enters the earnings report with strong technical momentum. The Barchart Technical Opinion currently stands at 100% Buy, up from 88% Buy one week ago and 88% Buy one month ago, indicating accelerating bullish sentiment as the stock approaches the release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings event
• Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the uptrend is well-established beyond just recent price action
• Long-term (100% Buy): Maximum bullish reading across the longer-term horizon reflects a sustained trend reversal from prior weakness

Trend Characteristics: The Strong and Strengthening trend profile suggests ZNTL is in an accelerating uptrend with improving momentum characteristics, providing a supportive technical backdrop for the earnings release.

The stock is trading at $4.88, positioned above all major moving averages—the 5-day ($4.77), 10-day ($4.63), 20-day ($4.73), 50-day ($4.27), 100-day ($3.96), and 200-day ($2.97). This alignment represents a bullish technical setup, with the stock having broken out from a prolonged base and now trading near its 52-week high of $6.95. The 200-day moving average at $2.97 highlights the magnitude of the rally—shares have gained over 64% from that long-term trend line. Key support now sits at the 20-day moving average around $4.73, while resistance lies at the recent high near $6.95. The overall technical picture is supportive heading into earnings, though the extended nature of the rally and elevated options-implied volatility suggest the stock could be vulnerable to profit-taking if results or guidance disappoint.